FDA Closes Manufacturing Module in Imricor’s PMA Submission

Manufacturing Module Acceptance Marks Major PMA Milestone

Imricor Medical Systems (ASX:IMR) has cleared a significant regulatory hurdle with the US Food and Drug Administration (FDA) accepting and closing the manufacturing module of its Premarket Approval (PMA) submission. This module, one of the most complex components of the PMA process, covers design, manufacturing, and quality controls for seven products, including the flagship Vision-MR Ablation Catheter and the RF-5000 Ablation Generator and Pump.

The FDA’s acceptance means this module will not be revisited during the final PMA review unless Imricor makes changes to its contents. This modular approach allows Imricor to progress through the FDA’s rigorous evaluation in stages, with the closure of the manufacturing module representing a tangible step forward in the path to full regulatory approval.

Scope of Manufacturing Module and Quality Controls

The manufacturing module encompasses a broad range of critical processes, including design controls, raw material inspection, build procedures, process validation, and device traceability. It also covers the quality management systems underpinning the production of six of Imricor’s own devices plus one third-party product that the company plans to distribute. Given the number of devices and the complexity involved, the FDA’s closure of this module signals strong confidence in Imricor’s manufacturing and quality frameworks.

Next Steps: FDA Pre-Approval Inspection and Final PMA Review

While the manufacturing module is closed, Imricor’s PMA journey is not yet complete. The FDA will conduct a pre-approval inspection of the company’s manufacturing sites before granting final PMA approval. This inspection is a standard but critical step to verify compliance with regulatory standards on-site. Final approval also depends on the satisfactory review of other PMA modules that Imricor is progressing through concurrently.

CEO Steve Wedan highlighted the significance of this milestone, noting that manufacturing is one of the most demanding aspects of any PMA submission. He described the FDA’s acceptance as a strong validation of Imricor’s design and production systems, underscoring the hard work invested by the team. Wedan also reaffirmed the company’s ongoing efforts across multiple FDA processes, including both 510(k) and PMA pathways, to support the US commercial launch of its electrophysiology platform.

Positioning for US Market Expansion

Imricor’s progress with the FDA aligns with its broader US commercial strategy, which has recently seen momentum through partnerships and product clearances. The company’s portfolio of MR-compatible devices aims to transform cardiac electrophysiology by enabling procedures under real-time magnetic resonance guidance rather than traditional x-ray fluoroscopy.

This regulatory milestone complements recent advances such as the launch of an integrated interventional MR lab solution with Philips, which combines Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, enhancing the clinical utility of Imricor’s technology in cardiac interventions. The FDA’s acceptance of the manufacturing module thus not only clears a regulatory checkpoint but also supports Imricor’s positioning in a growing market for radiation-free cardiac procedures.